BREXIT and its impact on the supply of medicines
The government recognizes the vital importance of medicines and medicinal products and is involved in implementing actions aimed at assuring the supply chain in the event of a no-deal Brexit. These include:
i) Requiring all pharmaceutical suppliers to ensure that they have a minimum of 6 weeks additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29th March 2019.
ii) Ensuring sufficient roll-on, roll-off freight capacity to enable medicines to move freely into the UK.
iii) Prioritising medicines and medicinal products on these alternative routes to ensure that the flow of all products will continue unimpeded after 29th March 2019.
The Secretary of State has emphasised the importance of healthcare providers not stockpiling additional medicines and medicinal products beyond business-as-usual levels.
In support of this, clinicians are requested to adhere to the Trust prescribing policy and avoid writing prescriptions for anything other than for a normal duration of supply. In most cases, this will represent a 28 day supply for regular medicines.
If you feel you are being put under pressure to provide additional supplies in the run up to Brexit or if you are encountering difficulties adhering to the out-patient prescribing policy, please contact David Pitkin, Chief Pharmacist, to discuss further.
Thank you in anticipation.